Chugai Pharmaceutical Building 48, known as FJ2, is an API facility for the manufacture of small and mid-size molecule drugs to be used for clinical development purposes. Located in the heart of Japan at a key transportation point, construction and commissioning of a new manufacturing center was completed at the Chugai Fujieda plant responsible for the supply of Active Pharmaceutical Ingredients (APIs) in August 2022.